TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 16545523

Group type: EXPERIMENTAL
Intervention: Lumbar fusion with posterior transpedicular screws
Number of subjects: 60

Group type: COMPARATOR
Intervention: Cognitive intervention and exercises
Number of subjects: 60
Study: 11948034

Group type: EXPERIMENTAL
Intervention: Megestrol acetate (MA), 800 mg/d oral suspension for 8 weeks
Number of subjects: 145

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 145
Study: 9500751

Group type: EXPERIMENTAL
Intervention: Salmeterol (42 microg twice daily for 12 weeks)
Number of subjects: 506
Study: 7895755

Group type: EXPERIMENTAL
Intervention: Milk formula B (26% oleic acid, 0.5% DHA, 0.12% AA)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Milk formula A (13% oleic acid, <0.05% AA, no DHA)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Breast milk
Number of subjects: 0
Study: 2634218

Group type: EXPERIMENTAL
Intervention: Nifedipine Retard
Number of subjects: 0

Group type: COMPARATOR
Intervention: Acebutolol
Number of subjects: 0
Study: 785936

Group type: EXPERIMENTAL
Intervention: Tranexamic acid (AMCA)
Number of subjects: 244

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 244
Study: 6454366

Group type: EXPERIMENTAL
Intervention: Sulfentanil (0.00015, 0.0003, 0.0006 mg/kg)
Number of subjects: 1

Group type: EXPERIMENTAL
Intervention: Morphine (0.100, 0.150, 0.200 mg/kg)
Number of subjects: 1

Group type: EXPERIMENTAL
Intervention: Fentanyl (not specified dosage)
Number of subjects: 1

Group type: EXPERIMENTAL
Intervention: Sulfentanil
Number of subjects: 1

Group type: EXPERIMENTAL
Intervention: Sulfentanil, Morphine, Fentanyl
Number of subjects: 1
Study: 30707002

Group type: EXPERIMENTAL
Intervention: Lean-EVs
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: MetS-EVs
Number of subjects: 10
Study: 27860526

Group type: EXPERIMENTAL
Intervention: MED ID survey (two-item survey)
Number of subjects: 126

Group type: EXPERIMENTAL
Intervention: MED ID scores ≥8 points
Number of subjects: 126
Study: 27477289

Group type: EXPERIMENTAL
Intervention: Antibody-mediated blockade of CD47 and targeting of CD271+ melanoma cells
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study: 24806481

Group type: EXPERIMENTAL
Intervention: Graphic warnings (GWs) designed by the FDA
Number of subjects: 1169

Group type: COMPARATOR
Intervention: No-label control
Number of subjects: 1169
Study: 21878579

Group type: EXPERIMENTAL
Intervention: Celecoxib dosed at 3 mg/kg bid
Number of subjects: 152

Group type: EXPERIMENTAL
Intervention: Celecoxib dosed at 6 mg/kg bid
Number of subjects: 152

Group type: EXPERIMENTAL
Intervention: 50 mg bid capsule (or sprinkles) for patients weighing 10 to 25 kg
Number of subjects: 152

Group type: EXPERIMENTAL
Intervention: 100 mg bid for patients >25 kg
Number of subjects: 152
Study: 18925413

Group type: EXPERIMENTAL
Intervention: 4 mg of salbutamol
Number of subjects: 8

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 8
Study: 17985057

Group type: EXPERIMENTAL
Intervention: FASTPlaque-Response (phage-based test)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Conventional drug susceptibility testing (DST)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Rifampicin-resistant strains
Number of subjects: 0
Study: 15718314

Group type: EXPERIMENTAL
Intervention: pegfilgrastim 6 mg subcutaneously on day 2 of each 21-day chemotherapy cycle
Number of subjects: 928
Study: 12523681

Group type: EXPERIMENTAL
Intervention: Home blood pressure measurement
Number of subjects: 87

Group type: COMPARATOR
Intervention: Office blood pressure measurement
Number of subjects: 87

Group type: EXPERIMENTAL
Intervention: Correlation between home and office readings
Number of subjects: 87

Group type: EXPERIMENTAL
Intervention: Morning and afternoon blood pressure measurements
Number of subjects: 87
Study: 10455832

Group type: EXPERIMENTAL
Intervention: SCOTI device
Number of subjects: 132

Group type: COMPARATOR
Intervention: Clinical auscultatory method
Number of subjects: 132

Group type: COMPARATOR
Intervention: Capnograph
Number of subjects: 132
Study: 7596183

Group type: EXPERIMENTAL
Intervention: Chemotherapy protocol adapted from the multicentre German study
Number of subjects: 74
Study: 2087879

Group type: EXPERIMENTAL
Intervention: CVD 103-HgR vaccine (5 x 10^8 viable organisms)
Number of subjects: 50

Group type: COMPARATOR
Intervention: E. coli K-12 placebo
Number of subjects: 50
Study: 620478

Group type: EXPERIMENTAL
Intervention: Oral chlormethiazole
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Intravenous chlormethiazole
Number of subjects: 0
Study: 31498682

Group type: EXPERIMENTAL
Intervention: CT-P10 (rituximab biosimilar)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Rituximab
Number of subjects: 0
Study: 28826192

Group type: EXPERIMENTAL
Intervention: Pridopidine 45 mg twice daily (BID)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Pridopidine 45 mg BID
Number of subjects: 0
Study: 26125298

Group type: EXPERIMENTAL
Intervention: AIDR 3D algorithm
Number of subjects: 2

Group type: COMPARATOR
Intervention: FBP algorithm
Number of subjects: 2
Study: 22926634

Group type: EXPERIMENTAL
Intervention: Instrument designed to identify risk factors for non-adherence to self-management behaviors
Number of subjects: 636

Group type: EXPERIMENTAL
Intervention: Composite variable levels representing the highest number of self-management non-adherence risk factors
Number of subjects: 636
Study: 21324028

Group type: EXPERIMENTAL
Intervention: Transfer of melanocytes and epidermal cells using the sandpaper method combined with dermabrasion
Number of subjects: 11

Group type: COMPARATOR
Intervention: Simple dermabrasion
Number of subjects: 11
Study: 19144760

Group type: EXPERIMENTAL
Intervention: Avosentan (5, 10, 25, and 50 mg)
Number of subjects: 286

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 286
Study: 17551149

Group type: EXPERIMENTAL
Intervention: Baseline plasma CRP level (highest quintile)
Number of subjects: 27919

Group type: COMPARATOR
Intervention: Baseline plasma CRP level (lowest quintile)
Number of subjects: 27919
Study: 14998845

Group type: EXPERIMENTAL
Intervention: Combination regimen of doxorubicin and docetaxel (60 mg/m2 each)
Number of subjects: 123

Group type: EXPERIMENTAL
Intervention: Alternating regimen of doxorubicin and docetaxel (100 mg/m2 DOC and 75 mg/m2 doxorubicin)
Number of subjects: 123

Group type: EXPERIMENTAL
Intervention: Sequential regimen of doxorubicin and docetaxel (100 mg/m2 DOC and 75 mg/m2 doxorubicin)
Number of subjects: 123

Group type: EXPERIMENTAL
Intervention: Combination regimen with prophylactic oral ciprofloxacin
Number of subjects: 123

Group type: COMPARATOR
Intervention: Combination regimen (60 mg/m2 each)
Number of subjects: 123
Study: 11773919

Group type: EXPERIMENTAL
Intervention: Eptifibatide
Number of subjects: 65

Group type: EXPERIMENTAL
Intervention: Closed myocardium (TMPG 0/1) or delayed myocardial perfusion (TMPG 2)
Number of subjects: 65
Study: 9688483

Group type: EXPERIMENTAL
Intervention: Wrapping of the legs
Number of subjects: 82

Group type: COMPARATOR
Intervention: No intervention (Control)
Number of subjects: 82

Group type: EXPERIMENTAL
Intervention: Elevation of the legs
Number of subjects: 82
Study: 7862935

Group type: EXPERIMENTAL
Intervention: Fluvoxamine 200 mg per day for 4 weeks
Number of subjects: 8

Group type: COMPARATOR
Intervention: Matched placebo for 4 weeks
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Fluvoxamine 200 mg per day
Number of subjects: 8
Study: 2816246

Group type: EXPERIMENTAL
Intervention: 5 mg of droperidol I.V. (n = 19)
Number of subjects: 130

Group type: EXPERIMENTAL
Intervention: 2.5 mg of droperidol I.V. (n = 30)
Number of subjects: 130

Group type: EXPERIMENTAL
Intervention: 0.5 mg of droperidol I.V. (n = 32)
Number of subjects: 130

Group type: COMPARATOR
Intervention: Normal saline (2 ml) (n = 49)
Number of subjects: 130
Study: 824860

Group type: EXPERIMENTAL
Intervention: amilorid (10 mg daily, orally) for two days
Number of subjects: 12

Group type: COMPARATOR
Intervention: potassium canrenoate (200 mg daily, i.v.) for two days
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: amilorid (10 mg daily) long-term treatment (up to 14 weeks)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: spironolactone (200 mg daily) long-term treatment (up to 14 weeks)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: chlortalidone (50 mg daily) long-term treatment (up to 14 weeks)
Number of subjects: 12
Study: 29377736

Group type: EXPERIMENTAL
Intervention: Family members' heroin use status
Number of subjects: 2446

Group type: EXPERIMENTAL
Intervention: Family support of MMT
Number of subjects: 2446

Group type: EXPERIMENTAL
Intervention: Family problems
Number of subjects: 2446
Study: 29095958

Group type: EXPERIMENTAL
Intervention: Friendship networks
Number of subjects: 14010

Group type: EXPERIMENTAL
Intervention: Family networks
Number of subjects: 14010

Group type: EXPERIMENTAL
Intervention: Photo networks
Number of subjects: 14010

Group type: EXPERIMENTAL
Intervention: Group networks
Number of subjects: 14010
Study: 25051389

Group type: EXPERIMENTAL
Intervention: 12-month multicomponent physical activity (PA) and fundamental movement skills (FMS) intervention
Number of subjects: 460

Group type: COMPARATOR
Intervention: Control group (not explicitly mentioned)
Number of subjects: 460
Study: 23997364

Group type: EXPERIMENTAL
Intervention: 10 mg tiagabine
Number of subjects: 14

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 14
Study: 21958795

Group type: EXPERIMENTAL
Intervention: Adhesive-enhanced closure with Kryptonite biocompatible adhesive
Number of subjects: 55

Group type: COMPARATOR
Intervention: Conventional wire closure
Number of subjects: 55
Study: 18245765

Group type: EXPERIMENTAL
Intervention: High-velocity varied resistance (HV)
Number of subjects: 67

Group type: EXPERIMENTAL
Intervention: Constant resistance (ST)
Number of subjects: 67

Group type: COMPARATOR
Intervention: Nontraining control (CO)
Number of subjects: 67
Study: 16750452

Group type: EXPERIMENTAL
Intervention: Fenofibrate 145 mg with ezetimibe 10 mg
Number of subjects: 18

Group type: COMPARATOR
Intervention: Fenofibrate 145 mg alone
Number of subjects: 18

Group type: COMPARATOR
Intervention: Ezetimibe 10 mg alone
Number of subjects: 18
Study: 14636761

Group type: EXPERIMENTAL
Intervention: OrCel
Number of subjects: 2

Group type: COMPARATOR
Intervention: Biobrane-L
Number of subjects: 2
Study: 10762192

Group type: EXPERIMENTAL
Intervention: 4‐Aminopyridine (4‐AP)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study: 8557900

Group type: EXPERIMENTAL
Intervention: Mibefradil 150 mg
Number of subjects: 126

Group type: EXPERIMENTAL
Intervention: Mibefradil 100 mg
Number of subjects: 126

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 126
Study: 1794819

Group type: EXPERIMENTAL
Intervention: Gentamicin eyedrops applied at 1-h intervals for at least 10 hours
Number of subjects: 50

Group type: COMPARATOR
Intervention: Half-strength povidone-iodine solution applied for 2 minutes
Number of subjects: 50
Study: 6349444

Group type: EXPERIMENTAL
Intervention: Rifampicin (600 mg daily for 6 weeks)
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: Prednisolone (increased dosage)
Number of subjects: 6

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 6
Study: 31549456

Group type: EXPERIMENTAL
Intervention: Contact force (CF) sensing ablation (TactiCath), 57% with optimal CF (≥90% lesion with ≥10g of CF)
Number of subjects: 279

Group type: COMPARATOR
Intervention: Ablation without CF measurement
Number of subjects: 279

Group type: EXPERIMENTAL
Intervention: Optimal CF
Number of subjects: 279

Group type: COMPARATOR
Intervention: Ablation without CF
Number of subjects: 279
Study: 30580725

Group type: EXPERIMENTAL
Intervention: Pioglitazone
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 28691952

Group type: EXPERIMENTAL
Intervention: Etanercept
Number of subjects: 29
Study: 25662699

Group type: EXPERIMENTAL
Intervention: PVI+SVCI
Number of subjects: 100

Group type: COMPARATOR
Intervention: PVI alone
Number of subjects: 100
Study: 24119734

Group type: EXPERIMENTAL
Intervention: Sequential interferon alpha‐1b (IFNa‐1b) for 6 months
Number of subjects: 20

Group type: COMPARATOR
Intervention: Telbivudine (LdT) treatment continued for an additional 6 months
Number of subjects: 20
Study: 21904013

Group type: EXPERIMENTAL
Intervention: Honey-coated dressing (Group A)
Number of subjects: 67

Group type: COMPARATOR
Intervention: Silver-coated dressing (Group B)
Number of subjects: 67

Group type: EXPERIMENTAL
Intervention: Both interventions (honey and silver dressings)
Number of subjects: 67
Study: 19445374

Group type: EXPERIMENTAL
Intervention: Intrauterine fetoscopic surgical treatment using a 2-mm endoscope and diode laser fiber, performed under local anesthesia, through a single 3-mm trocard.
Number of subjects: 0

Group type: COMPARATOR
Intervention: Serial amnioreduction
Number of subjects: 0
Study: 17033544

Group type: EXPERIMENTAL
Intervention: Computerized tailored brief advice
Number of subjects: 1139

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 1139
Study: 14649785

Group type: EXPERIMENTAL
Intervention: Guided self-change (self-care manual plus eight fortnightly sessions of cognitive behavioural therapy)
Number of subjects: 28

Group type: COMPARATOR
Intervention: Cognitive behavioural therapy (16 weekly sessions)
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: Both groups (Guided self-change and CBT)
Number of subjects: 28
Study: 10783405

Group type: EXPERIMENTAL
Intervention: Gastric lavage
Number of subjects: 10

Group type: COMPARATOR
Intervention: Control (no gastric lavage)
Number of subjects: 10
Study: 8999458

Group type: EXPERIMENTAL
Intervention: Erythropoietin (EPO) administered intravenously at a dose of 50 U/kg body mass
Number of subjects: 7

Group type: COMPARATOR
Intervention: Healthy controls (6 subjects: 4 males and 2 females)
Number of subjects: 7
Study: 8434742

Group type: EXPERIMENTAL
Intervention: Continuous infusion of fentanyl at a rate of 50 micrograms.h‐1 with additional epidural boluses (25 micrograms) as required
Number of subjects: 43

Group type: EXPERIMENTAL
Intervention: Patient-controlled analgesia using a 25 microgram epidural bolus of fentanyl with a 15 min lock‐out period
Number of subjects: 43

Group type: EXPERIMENTAL
Intervention: Combination of patient-controlled analgesia and continuous infusion
Number of subjects: 43

Group type: COMPARATOR
Intervention: Nurse-administered analgesia (implied control)
Number of subjects: 43
Study: 2957210

Group type: EXPERIMENTAL
Intervention: 400 mg CM 57755
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: 0.5 g CM 57755
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: 1.0 g CM 57755
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: 800 mg cimetidine
Number of subjects: 16

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 16
Study: 30372111

Group type: COMPARATOR
Intervention: Contrast condition (between-category comparisons)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Match condition (same-category comparisons)
Number of subjects: 0
Study: 26211531

Group type: EXPERIMENTAL
Intervention: Resistance training based physical activity program with weekly discussions on health and quality of life (Mental group)
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: Resistance training based physical activity program (Physical activity group)
Number of subjects: 45

Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 45
Study: 24330490

Group type: EXPERIMENTAL
Intervention: iRoot BP
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: MTA
Number of subjects: 24
Study: 24502374

Group type: EXPERIMENTAL
Intervention: Intervention that challenged beliefs about the effectiveness of various quit methods
Number of subjects: 245

Group type: COMPARATOR
Intervention: No-intervention controls
Number of subjects: 245
Study: 22179532

Group type: EXPERIMENTAL
Intervention: 6-month DAPT
Number of subjects: 1443

Group type: COMPARATOR
Intervention: 12-month DAPT
Number of subjects: 1443

Group type: EXPERIMENTAL
Intervention: 6-month DAPT (in diabetic patients)
Number of subjects: 1443

Group type: COMPARATOR
Intervention: 12-month DAPT (in diabetic patients)
Number of subjects: 1443
Study: 20378585

Group type: EXPERIMENTAL
Intervention: 16 mg ENDD
Number of subjects: 40

Group type: COMPARATOR
Intervention: 0 mg ENDD (placebo)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Nicorette nicotine inhalator
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Cigarettes
Number of subjects: 40
Study: 18055721

Group type: EXPERIMENTAL
Intervention: Endometrial ablation
Number of subjects: 237

Group type: EXPERIMENTAL
Intervention: Hysterectomy
Number of subjects: 237
Study: 16075692

Group type: EXPERIMENTAL
Intervention: Crisis experience in individuals with SPMI
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Immediate responses to crises
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Factors contributing to crisis resolution and prevention
Number of subjects: 0
Study: 12169041

Group type: EXPERIMENTAL
Intervention: Desloratadine 7.5mg under fed conditions
Number of subjects: 18

Group type: COMPARATOR
Intervention: Desloratadine 7.5mg under fasted conditions
Number of subjects: 18
Study: 10850247

Group type: EXPERIMENTAL
Intervention: One‐Step adhesive with AEliteflo
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: One‐Step adhesive with Bisco Glaze
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: One‐Step adhesive with Silux Plus
Number of subjects: 14
Study: 8784084

Group type: COMPARATOR
Intervention: Methimazole alone (Group 1)
Number of subjects: 70

Group type: EXPERIMENTAL
Intervention: 30 mg methimazole daily plus sufficient T4 to maintain TSH in the high-normal range (Group 2)
Number of subjects: 70

Group type: EXPERIMENTAL
Intervention: 30 mg methimazole daily plus sufficient T4 to suppress TSH to below 0.6 mIU/L (Group 3)
Number of subjects: 70
Study: 1473391

Group type: EXPERIMENTAL
Intervention: Succinylcholine 1 mg/kg i.v. under normal condition (PetCO2 5‐5.5kPa)
Number of subjects: 15

Group type: COMPARATOR
Intervention: Succinylcholine 1 mg/kg i.v. under hyperventilation (PetCO2 3‐3.5kPa)
Number of subjects: 15
Study: 6734304

Group type: EXPERIMENTAL
Intervention: Rectal administration of bacampicillin hydrochloride (400 mg)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Oral administration of bacampicillin hydrochloride (400 mg)
Number of subjects: 12
Study: 30609152

Group type: EXPERIMENTAL
Intervention: Risperidone (continued treatment group)
Number of subjects: 25

Group type: COMPARATOR
Intervention: Placebo (discontinuation group)
Number of subjects: 25
Study: 29812983

Group type: EXPERIMENTAL
Intervention: Checklist group
Number of subjects: 43

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 43
Study: 26897490

Group type: EXPERIMENTAL
Intervention: Liposomal bupivacaine (LB) periarticular injection, n = 20
Number of subjects: 38

Group type: COMPARATOR
Intervention: Standard periarticular injection (ropivacaine, clonidine, Toradol, Epinepherine, saline), n = 18
Number of subjects: 38
Study: 24690101

Group type: EXPERIMENTAL
Intervention: Proactive palliative care with regular consultations from a specialized palliative care team for patients meeting two or more criteria of the set of indicators.
Number of subjects: 6

Group type: COMPARATOR
Intervention: Standard care (usual care) for all patients in the study.
Number of subjects: 6
Study: 21883656

Group type: EXPERIMENTAL
Intervention: Laparoscopic anterior partial fundoplication (AF)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Laparoscopic Nissen fundoplication (NF)
Number of subjects: 100
Study: 20574936

Group type: EXPERIMENTAL
Intervention: Hypnoreflexogenous birth preparation course
Number of subjects: 101

Group type: COMPARATOR
Intervention: Control group (hospital birth register 2001-2008)
Number of subjects: 101
Study: 18271226

Group type: EXPERIMENTAL
Intervention: Needling method of harmonizing spleen-stomach (acupuncture at specific points)
Number of subjects: 130

Group type: COMPARATOR
Intervention: Routine diabetic therapy with acupuncture at specific points (control group)
Number of subjects: 130
Study: 15952402

Group type: EXPERIMENTAL
Intervention: Neridronate (25 mg monthly injection) + Calcium (500 mg daily) + Vitamin D (400 U daily)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Calcium (500 mg daily) + Vitamin D (400 U daily)
Number of subjects: 40
Study: 12003578

Group type: EXPERIMENTAL
Intervention: Adenotonsillectomy
Number of subjects: 101
Study: 10462651

Group type: EXPERIMENTAL
Intervention: Lifting (Group A)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Non-lifting (Group B)
Number of subjects: 60
Study: 7596123

Group type: EXPERIMENTAL
Intervention: Molsidomine retard 8 mg
Number of subjects: 50

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 50
Study: 1486070

Group type: EXPERIMENTAL
Intervention: 3% acyclovir ointment and 0.1% betamethasone (Betnesol) drops
Number of subjects: 30

Group type: COMPARATOR
Intervention: Acyclovir ointment and matching placebo
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 30
Study: 6489764

Group type: EXPERIMENTAL
Intervention: Co-dergocrine mesylate (Hydergine) 1.5 three times daily
Number of subjects: 99

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 99
Study: 30017006

Group type: EXPERIMENTAL
Intervention: Incredible Years® Teacher Classroom Management (TCM) programme
Number of subjects: 2075

Group type: COMPARATOR
Intervention: Teaching As Usual (TAU)
Number of subjects: 2075
Study: 30132010

Group type: EXPERIMENTAL
Intervention: Active transcranial direct current stimulation
Number of subjects: 12

Group type: COMPARATOR
Intervention: Sham transcranial direct current stimulation
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Breathing-controlled electrical stimulation (combined with either active or sham transcranial direct current stimulation)
Number of subjects: 12
Study: 27729533

Group type: EXPERIMENTAL
Intervention: Reading intervention focusing on the malleability of reading abilities and praising effort; details on dosage and duration not available.
Number of subjects: 1587

Group type: EXPERIMENTAL
Intervention: Reading intervention; details on dosage and duration not available.
Number of subjects: 1587
Study: 24196263

Group type: EXPERIMENTAL
Intervention: Microwave ablation (MWA) for 10 min
Number of subjects: 40

Group type: COMPARATOR
Intervention: Internally cooled radiofrequency ablation (RFA) for 12 min
Number of subjects: 40
Study: 22012861

Group type: EXPERIMENTAL
Intervention: Sugammadex 2 mg kg(‐1) of corrected body weight (Group SUG)
Number of subjects: 70

Group type: COMPARATOR
Intervention: Neostigmine 0.05 mg kg(‐1) of corrected body weight (Group NEO)
Number of subjects: 70
Study: 20682754

Group type: EXPERIMENTAL
Intervention: Computer-generated faces with varying gender dimensions
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Real faces with gendered facial cues
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Use of gendered cues in sexual orientation judgments
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Judgments of targets countering stereotypes
Number of subjects: 0